Trial
NCT00740545
Prevention of Unexplained Recurrent Abortion by Enoxaparine
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
University Hospital, Brest
Collaborators
—
Condition
Alive and Viable Births
Intervention
enoxaparine 40 mg daily
Why stopped
Stopped for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-05